Zerlasiran was found to be well tolerated and no significant safety concerns were observed. Credit: Good dreams - Studio via ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

For those choosing to go vegan, the doctor said, it’s important to “increase soluble fiber, focus on whole foods, which are ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns ...

This innovative treatment could offer a major breakthrough for patients struggling with elevated Lp (a). Credit: Tada Images ...

Eli Lilly said the treatment, a once-daily pill called muvalaplin, showed reductions in Lp (a) levels compared to placebo. Injectables are currently in Phase 3 development, but "these are the first ...

Eli Lilly said a Phase 2 clinical trial for its treatment to inhibit lipoprotein(a) formation met its primary endpoint. Eli Lilly said the treatment, a once-daily pill called muvalaplin ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...